focus -WSS

focus

author：leisure time 2025-10-02 22:27:18 - browse：9923

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Questions loom on AstraZeneca cancer drug as safety concerns ebb

WSS

Francis Collins on trust in science and how Covid communications failed

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Parkinson’s finding may lead to tests and, someday, treatments

EU regulator recommends expanding Mounjaro approval to obesity

STAT Readout: Friday, Oct. 20 biotech updates

ADCs take center stage as promising cancer treatments

entertainment

focus

leisure time

New air purifier tech could be key to improving indoor air quality

Copay coupons to count toward deductibles, after Biden court move

Moonlake's readout produced a cash windfall. Risks remain

New brain studies show LSD's effects on the brain in full color

Virginia high school admissions case could be legal follow

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Parkinson’s finding may lead to tests and, someday, treatments

focus

AI generated plenty of interest at JPM but not a lot of trust

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Smaller biotechs seek to piggyback on weight loss drug boom

Test for long Covid? Researchers find new clue in blood samples

Study on Amgen’s bispecific immunotherapy produces positive data

eGenesis tests gene

knowledge

knowledge

Wikipedia

leisure time